|  |
| --- |
| OFFICE USE |

|  |
| --- |
|  |
|  |
|  |

|  |
| --- |
|  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **APPLICATION FORM**  **24th Annual Meeting of JSGCT 2018** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **Please carefully fill in this form and submit with your abstract through the**  **Conference Website http://jsgct24.umin.jp/en/index.html** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Last Name: | | | | |  | | | | | | First: | | | |  | | | Middle: | | | | | |  |  | | Degrees: | | | |  |
| Affiliated Institution: | | | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | |
| Address: | | | |  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| City: | |  | | | | | | | | | | | | | | | | | | | | | State: | |  | | | | | | |
| Zip: | |  | | | | | | | | Country: | | | |  | | | | | | | | | DOB (DD/MM/YY): | | | | | | |  | |
| Phone Number | | | | | | ( | |  | | | | ) |  | | | | | | | | | | Fax Number | | | | | |  | | |
| E-mail address: | | | | | | |  | | | | | | | | | | | | | | | | | | | | | | | | |
| **Title of abstract:** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Please choose abstract categories (one or several): | | | | | | | | | | | | | | | | |  | | | | | | | | | | | | | | |
| 1. **Basic science and technologies**   A1. Gene regulation  A2. Genome editing  A3. Oligonucleotides  A4. RNAi technologies and miRNA  A5. Stem cells (include ES cells and iPS cells)  A6. Tissue engineering  A7. Cell processing  A8. Bioimaging  A9. Immune/Inflammation regulation  A10. Others  **B. Vector development and gene transfer technologies**  B1. Viral vectors  B2. Non-viral vectors  B3. Other gene transfer technologies | | | | | | | | | | | | | | | | | | | | | **C. Preclinical studies for gene and cell therapy**  (include studies for molecular pathogenesis)  C1. Genetic diseases  C2. Cancer  C3. Cardiovascular diseases  C4. Neurologic, ophthalmic, and musculo-skeletal diseases  C5. Infectious diseases and vaccines  C6. Cell therapy  C7. Regenerative medicine  C8. Others   1. **Clinical studies for gene and cell therapy**   D1. Genetic diseases  D2. Cancer  D3. Cardiovascular diseases  D4. Neurologic, ophthalmic, and musculo-skeletal diseases  D5. Infectious diseases and vaccines  D6. Cell therapy  D7. Others | | | | | | | | | | |
| **Presentation Format** (Please note that there may be cases that we cannot meet your request.) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1) Select your presentation format: | | | | | | | | | | | | | |  | | Oral | | |  | Poster | | | | | |  | | Either | | | |
| 2) For authors who selected Oral Presentation: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| I prefer to make my presentation in English | | | | | | | | | | | | | | | | | | | | |  | Yes | | | | | | | | | |
| **Disclosure of Relevant Conflict of Interest (COI)** **in connection with the above mentioned presentation**  **for all authors (including co-authors)** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  |  | | No, we do not have any COI with any company and/or organization. | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  |  | | Yes, we have COI with the following company(ies) and/or organization(s) listed below. | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| **If yes, please precisely complete the list below on all of authors (including co-authors)** | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|  | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

**24th Annual Meeting of Japan Society of Gene and Cell Therapy**

**Conflict of Interest Disclosure statement by author**

|  |
| --- |
| Name of Author |
|  |
| Title of Presentation |
|  |

In connection with the above-mentioned presentation, report the names of any companies and organizations and state

the Conflict of Interest for each entry.

\*Any COI during the past 12 months should be disclosed at the time of abstract submission.

|  |  |  |
| --- | --- | --- |
| Entry | Status | If yes, provide the name of the company  and /or organization |
| 1. Postemployment/leadership   position/advisory role in companies or profit-oriented organizations, and  compensation related to the post.  (More than one million yen per year from one company/organization) | Self:  Yes / No |  |
| Family:  Yes / No |  |
| 1. Stock ownership and profits from stock ownership.   (More than one million yen per or 5% per year from one company/organization) | Self:  Yes / No |  |
| Family:  Yes / No |  |
| 1. Patent royalties/licensing fees paid by companies and profit-oriented   organizations.  (More than one million yen per patent per year) | Self:  Yes / No |  |
| Family:  Yes / No |  |
| 1. Honoraria (e.g. lecture fees) paid by   companies and profit-oriented  organizations to compensate for  attendance (presentation) at  meeting/s.  (More than one million yen in total per year from one company/organization) | Self:  Yes / No |  |
| 1. Manuscript fees paid by companies and profit-oriented organizations for writing promotional material (e.g. brochures)   (More than one million yen in total per year from one company/organization) | Self:  Yes / No |  |
| 1. Research funding (clinical trial, sponsored or funded research, collaborative research etc.) provided by companies and profit-oriented organizations.   (More than one million yen in total per year from one company/organization) | Self:  Yes / No |  |
| 1. Scholarship contributions from companies and profit-oriented   organizations.  (More than two million yen in total per year from one company/organization) | Self:  Yes / No |  |
| 1. Study group sponsorship by companies and profit-oriented organizations.   (The researcher belongs to study group) | Self:  Yes / No |  |
| 1. Payments from companies and profit-oriented organizations for anything unrelated to research, education, or medical practice.   (More than fifty thousand yen in total per year from one company/organization) | Self:  Yes / No |  |

\*Report on the lead presenter him/herself, his/her spouse, first-degree relatives, and anyone who shares his/her

income and wealth.

NOTE 1: This COI Disclosure Statement will be kept on file for 5 years after the meeting presentation.

However, any statements relating to rejected presentations will be destroyed immediately and will not be returned to

the presenter.

NOTE 2: The COI of authors must be appropriately managed by his/her academic institutions COI committee.

If not, please take appropriate steps at your own institution by the time of abstract submission

Date of disclosure: